Cytosorbents (CTSO) Tops Q4 EPS by 2c, Misses on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St falls as oil ticks up, yields rise ahead of US-China summit
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil up almost 2% as Iran's president vows to never surrender
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
March 31, 2025 4:16 PM EDT2024 marked by strong commercial execution and improved operating leverageCompany continues to expect DrugSorb-ATR regulatory decisions from Health Canada and US FDA in 2025 Successful Rights Offering and exercise of Series A Right Warrants strengthens balance sheetStrengthening of clinical portfolio across cardiac surgery and critical care in 2025 with new presentations and publications The Company has now adopted the standard accounting convention of reporting Revenue to... More
